Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $70 from $58 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $76 from $60 at Truist
- Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital
- Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright
- Protagonist reports top line results from Phase 2b study of icotrokinra
- Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies
Questions or Comments about the article? Write to editor@tipranks.com